Autoimmune, Inflammatory-Focused Biotech Odyssey Files for IPO
Odyssey Therapeutics Inc. filed for a US initial public offering, joining a growing pool of drug developers seeking to advance public listing plans amid robust investor demand for biotech stocks.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.